1-2 of 2
Claude Gardin, MD PhD
Close
Sort by
Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Norbert Vey, Pierre-Yves Dumas, MD, Christian Recher, MD PhD, Lauris Gastaud, MD, Bruno Lioure, MD, Claude-Eric Bulabois, MD, Cecile Pautas, Jean-Pierre Marolleau, MD PhD, Stéphane Leprêtre, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD, Yosr Hicheri, Caroline Bonmati, MD, Bruno Quesnel, MD PhD, Philippe Rousselot, Sylvie Castaigne, MD PhD, Eric Jourdan, MD, Jean Valère Malfuson, Gaelle Guillerm, MD, Jean Henri Bouhris, Mario Ojeda, MD, Mathilde Hunault, MD PhD, Norbert Ifrah, MD PhD, Claude Gardin, MD PhD, Andre Delannoy, MD, Lucile Beautier, Carine Paturel, PhD, Pascale Andre, PhD, Robert Zerbib, Claude Preudhomme, PharmD, PhD, Antoine Toubert, MD PhD, Nicolas Dulphy, PhD, Daniel Olive, MD PhD, Arnaud Pigneux, MD, Herve Dombret, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 889.
https://doi.org/10.1182/blood.V130.Suppl_1.889.889
Published: 2017
Journal Articles

Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Lionel Ades, MD PhD, Emmanuel Raffoux, MD, Olivier Spertini, Agnès Guerci, MD PhD, Christian Recher, MD PhD, Denis Guyotat, Eric Deconinck, MD PhD, Thierry Lamy De La Chapelle, Xavier Thomas, MD PhD, Dominique Bordessoule, MD PhD, Norbert Vey, Stephane de Botton, Arnaud Pigneux, MD, Denis Caillot, Jean-Yves Cahn, MD, Patrice Chevallier, MD PhD, Jean-Francois Lambert, MD, Claude Gardin, MD PhD, Herve Dombret, Julie Lejeune, Sylvie Chevret, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2016) 128 (22): 895.
https://doi.org/10.1182/blood.V128.22.895.895
Published: 2016